BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...majority shareholder Van Herk Investments B.V., will own 44% of the resulting company.TARGETS IGF1R (CD221) – Insulin-like growth factor-1...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...Epidermal growth factor receptor 2 IGF1R (CD221) – Insulin-like growth factor-1...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...Muscarinic acetylcholine receptor M1 CHRM4 (HM4) - Muscarinic acetylcholine receptor M4 IGF1R (CD221) - Insulin-like growth factor-1...
BioCentury | Jul 29, 2020

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

...of that.” The company’s lead program is Ent001, a mAb that inhibits the interaction of IGFBP3...
...molecule in development that inhibits the IGFBP3/TMEM219 interaction. Enthera was founded on research showing excessive IGFBP3... most advanced is Auges Therapeutics, which is focused on age-related diseases. Targets IGFBP3 - Insulin-like growth factor (IGF) binding protein 3...
BioCentury | Jul 18, 2020

Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

...studies in 2021, as well as build out its manufacturing infrastructure. Targets IGF1R (CD221) - Insulin-like growth factor-1...
BioCentury | Jun 27, 2020

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...but remains well above its 2020 low of $2.98 on March 18. Targets IGF-1 - Insulin-like growth factor-1...
BioCentury | Jun 26, 2020

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...cap of €253.2 million. Trading is expected to begin June 29. Targets IGF1R (CD221) - Insulin-like growth factor-1...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

...E (APOE) epsilon 4 EGFR (ErbB1; HER1) - Epidermal growth factor receptor IGF2R (M6PR) - Insulin-like growth factor-2...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...Patents: Undisclosed Targets GCK (GK) - Glucokinase GLP-1R 9GLP1R) - Glucagon-like peptide-1 receptor IGF-1 - Insulin-like growth factor-1...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...meeting. Targets DPP-1 (CTSC) - Dipeptidyl peptidase-1 ELANE (NE; HLE) - Neutrophil elastase IGF-1 - Insulin-like growth factor-1 Sandi...
Items per page:
1 - 10 of 716